IL174380A0 - Consensus/ancestral immunogens - Google Patents

Consensus/ancestral immunogens

Info

Publication number
IL174380A0
IL174380A0 IL174380A IL17438006A IL174380A0 IL 174380 A0 IL174380 A0 IL 174380A0 IL 174380 A IL174380 A IL 174380A IL 17438006 A IL17438006 A IL 17438006A IL 174380 A0 IL174380 A0 IL 174380A0
Authority
IL
Israel
Prior art keywords
consensus
ancestral immunogens
ancestral
immunogens
Prior art date
Application number
IL174380A
Other languages
English (en)
Original Assignee
Univ California
Univ Duke
Haynes Barton F
Hua Xin Liao
Univ Alabama At
Feng Gao
Bette T Korber
Beatrice H Hahn
George M Shaw
Denise Kothe
Ying Ying Li
Julie Decker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Duke, Haynes Barton F, Hua Xin Liao, Univ Alabama At, Feng Gao, Bette T Korber, Beatrice H Hahn, George M Shaw, Denise Kothe, Ying Ying Li, Julie Decker filed Critical Univ California
Publication of IL174380A0 publication Critical patent/IL174380A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL174380A 2003-09-17 2006-03-16 Consensus/ancestral immunogens IL174380A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60472204P 2004-08-27 2004-08-27
PCT/US2004/030397 WO2005028625A2 (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Publications (1)

Publication Number Publication Date
IL174380A0 true IL174380A0 (en) 2006-08-01

Family

ID=34381074

Family Applications (3)

Application Number Title Priority Date Filing Date
IL174380A IL174380A0 (en) 2003-09-17 2006-03-16 Consensus/ancestral immunogens
IL202249A IL202249A (en) 2003-09-17 2009-11-19 Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
IL230011A IL230011A0 (en) 2003-09-17 2013-12-17 Coordination immunogens/progenitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL202249A IL202249A (en) 2003-09-17 2009-11-19 Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
IL230011A IL230011A0 (en) 2003-09-17 2013-12-17 Coordination immunogens/progenitors

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP2371387A3 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20120086379A (enExample)
CN (2) CN1852734B (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2918585C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785143B2 (en) 2000-02-04 2006-10-05 Beth Israel Deaconess Medical Center Human immunodeficiency virus vaccine
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
EP1800126B1 (en) 2004-09-08 2014-12-17 The United States of America as represented by the Secretary of Health and Human Services, NIH Compositions and methods for the detection of hiv-1/hiv-2 infection
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US7951377B2 (en) * 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
DK2392587T3 (en) * 2006-03-10 2016-05-23 Peptcell Ltd Peptide sequences and compositions
EP2001459B1 (en) * 2006-03-29 2012-07-11 Dana-Farber Cancer Institute, Inc. Methods and compositions for inducing an immune response to hiv and models for testing
WO2007143606A2 (en) * 2006-06-02 2007-12-13 International Aids Vaccine Initiative Hiv-1 clade a consensus sequences, antigens, and transgenes
ES2706501T3 (es) 2006-07-28 2019-03-29 Univ Pennsylvania Vacunas de VIH mejoradas
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US20100104596A1 (en) * 2007-03-27 2010-04-29 The Regents Of The University Of California Acutte transmitted hiv envelope signatures
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
AU2011219025A1 (en) * 2010-02-25 2012-09-27 Duke University Method of inducing the production of protective anti-HIV-1 antibodies
US20130177583A1 (en) * 2010-03-03 2013-07-11 Duke University Molecular clone of hiv-1
US20130273103A1 (en) * 2010-09-28 2013-10-17 Los Alamos National Security, Llc Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2013131099A1 (en) 2012-03-02 2013-09-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
WO2014151687A2 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods to treat aids
WO2015057950A1 (en) * 2013-10-16 2015-04-23 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
CA3016352A1 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3747463A1 (en) * 2016-09-15 2020-12-09 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2020072169A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
WO2023192971A2 (en) * 2022-03-31 2023-10-05 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2001060838A2 (en) 2000-02-18 2001-08-23 University Of Washington Aids ancestral viruses and vaccines
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Also Published As

Publication number Publication date
AU2004274937A2 (en) 2005-03-31
EP2371387A2 (en) 2011-10-05
CN1852734B (zh) 2010-12-01
KR20120086379A (ko) 2012-08-02
CN102010463A (zh) 2011-04-13
IL202249A (en) 2015-08-31
WO2005028625A3 (en) 2005-06-02
AU2004274937A1 (en) 2005-03-31
JP2007505624A (ja) 2007-03-15
EP1667714A4 (en) 2008-09-24
EP1667714A2 (en) 2006-06-14
BRPI0414443A (pt) 2006-11-21
US20180296665A1 (en) 2018-10-18
IL230011A0 (en) 2014-01-30
US9844589B2 (en) 2017-12-19
US8071107B2 (en) 2011-12-06
CA2539325A1 (en) 2005-03-31
EP1667714B1 (en) 2018-01-03
JP2014079250A (ja) 2014-05-08
AU2004274937B9 (en) 2011-04-14
WO2005028625A2 (en) 2005-03-31
EP2371387A3 (en) 2012-01-25
KR20070028291A (ko) 2007-03-12
US10946090B2 (en) 2021-03-16
JP4773352B2 (ja) 2011-09-14
CA2918585A1 (en) 2005-03-31
US20070178562A1 (en) 2007-08-02
JP6165612B2 (ja) 2017-07-19
CA2918585C (en) 2019-05-21
JP2011136997A (ja) 2011-07-14
CA2539325C (en) 2016-03-22
AU2004274937B2 (en) 2011-03-24
HK1097446A1 (en) 2007-06-29
US20120087938A1 (en) 2012-04-12
CN1852734A (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
IL230011A0 (en) Coordination immunogens/progenitors
AU157771S (en) Orthotic
AU156929S (en) Orthotic
EP1613260A4 (en) Soother
SI1594840T1 (sl) Derivati piperidin-benzensulfonamida
GB0317665D0 (en) Qinazoline derivatives
PT1682493E (pt) Derivados de aminoacetonitrilo
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
GB0323190D0 (en) Bed
GB0323258D0 (en) Therapeutic compounds
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
GB0309613D0 (en) Improved highchair
PT1706373E (pt) Derivados de amidoacetonitrilo
GB0321091D0 (en) Synthesis
EP1491205A4 (en) MEANS FOR THE TREATMENT OF HYPERMYOTONIA
PL1667537T3 (pl) Preparat dla niemowląt
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB2422833B (en) Zaleplon synthesis
GB0325049D0 (en) Improved highchair
GB0329319D0 (en) Synthesis
GB0328827D0 (en) Infant carrying aid
PL359876A1 (en) Anatomical pillow
AU154745S (en) Infant buggy-seat
GB0228977D0 (en) Infant carrying aid
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives